HilleVax, Inc. (NASDAQ:HLVX) Receives $3.00 Average PT from Analysts

Shares of HilleVax, Inc. (NASDAQ:HLVX) have received an average recommendation of “Hold” from the six brokerages that are presently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold recommendation. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $3.00.

Separately, HC Wainwright restated a “neutral” rating and issued a $2.00 target price on shares of HilleVax in a research note on Monday.

HilleVax Stock Performance

Shares of HLVX stock opened at $1.50 on Monday. The firm has a market cap of $74.71 million, a price-to-earnings ratio of -0.48 and a beta of 0.76. HilleVax has a 52 week low of $1.37 and a 52 week high of $16.31. The firm’s 50-day simple moving average is $1.79 and its two-hundred day simple moving average is $1.86.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings results on Friday, March 28th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.02). Analysts forecast that HilleVax will post -2.64 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Takeda Pharmaceutical Co. Ltd. purchased a new position in shares of HilleVax in the fourth quarter valued at $13,919,000. Lightspeed Management Company L.L.C. purchased a new stake in HilleVax during the 4th quarter worth about $4,847,000. JPMorgan Chase & Co. grew its holdings in HilleVax by 1,376.8% during the 4th quarter. JPMorgan Chase & Co. now owns 207,151 shares of the company’s stock valued at $429,000 after buying an additional 193,124 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of HilleVax during the third quarter valued at about $331,000. Finally, Millennium Management LLC boosted its position in shares of HilleVax by 59.6% in the fourth quarter. Millennium Management LLC now owns 411,820 shares of the company’s stock valued at $852,000 after acquiring an additional 153,815 shares during the period. 86.42% of the stock is owned by institutional investors.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.